Nigel Bundred
Overview
Explore the profile of Nigel Bundred including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gellert P, Segal C, Gao Q, Lopez-Knowles E, Martin L, Dodson A, et al.
Nat Commun
. 2016 Nov;
7:13294.
PMID: 27827358
Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in...
12.
Schmid P, Pinder S, Wheatley D, Macaskill J, Zammit C, Hu J, et al.
J Clin Oncol
. 2016 Mar;
34(17):1987-94.
PMID: 26976426
Purpose: Preclinical data support a key role for the PI3K pathway in estrogen receptor-positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative...
13.
Forbes J, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al.
Lancet
. 2015 Dec;
387(10021):866-73.
PMID: 26686313
Background: Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective...
14.
Leary A, Evans A, Johnston S, AHern R, Bliss J, Sahoo R, et al.
Clin Cancer Res
. 2014 Nov;
21(13):2932-40.
PMID: 25398453
Purpose: Not all breast cancers respond to lapatinib. A change in Ki67 after short-term exposure may elucidate a biomarker profile for responsive versus nonresponsive tumors. Experimental Design: Women with primary...
15.
Pieri A, Harvey J, Bundred N
World J Clin Oncol
. 2014 Aug;
5(3):546-53.
PMID: 25114868
The clinical significance of pleomorphic lobular carcinoma in situ (PLCIS) is a subject of controversy. As a consequence, there is a risk of providing inconsistent management to patients presenting with...
16.
17.
Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, et al.
Invest New Drugs
. 2013 Jan;
31(4):949-58.
PMID: 23315029
Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. In this dose-finding study,...
18.
Bundred N
Cancer Treat Rev
. 2012 Feb;
38(6):776-86.
PMID: 22370427
Bone health is an emerging concern in the early breast cancer setting. Current adjuvant therapies, especially hormonal therapies in premenopausal patients (e.g. goserelin) and aromatase inhibitors in postmenopausal patients, have...
19.
Evans D, Harvie M, Bundred N, Howell A
J Med Genet
. 2010 Oct;
47(12):853-5.
PMID: 20972247
Background: Uptake of cancer trials and in particular prevention trials has been disappointing globally. Methods: Uptake to three randomised chemotherapy breast cancer prevention trials and two dietary prevention trials in...
20.
Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, et al.
Oncologist
. 2008 Jun;
13(5):503-14.
PMID: 18515735
Background: The interim (12-month) results of two similarly designed, ongoing studies (the Zometa-Femara Adjuvant Synergy Trials [Z-FAST and ZO-FAST]) suggest that zoledronic acid (4 mg intravenously every 6 months) when...